← Leaderboards
Steven Isaacman
Nanometics, Llc
$10,967,667
Attributed
$13,611,823
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2011–24$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,611,823 · 14
By mechanism
R44$11,594,803 · 6
R43$1,792,020 · 7
R41$225,000 · 1
Top collaborators
- Seetharama A Acharya3 shared
- Eric K Rowinksy3 shared
- Charles Richard Esther1 shared
- Vern L. Schramm1 shared
Most similar at Nanometics, Llc
Same institution · by research overlap
- Eric K Rowinksy$999,624
- Andrew B Mahon$2,030,376
Others in their field
Top investigators on “Technological Innovation”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$303,754,336
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$240,302,862
- Richard A Gibbs · Baylor College Of Medicine$236,845,267
- David Heimbrook · Leidos Biomedical Research, Inc.$221,646,720
- Dennis R. Burton · Scripps Research Institute$199,212,539
- George R Seage · Abt Associates, Inc.$171,638,284
Research focus
Technological InnovationCommercial ApplicationSuccessSmall Business Innovation Research GrantBiotechnologyToxic EffectMalignant NeoplasmsTechnologyDoseSafetyDesignAffinityMarketingUnited StatesAmericanUnited States National Institutes Of HealthExhibitsBiological SciencesReportingFundingInnovationOralPharmaceutical PreparationsSkin
Grant awards (21)
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis$1,000,000
R44 · FY2024 · CA · contact PI
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis$1,000,000
R44 · FY2023 · CA · contact PI
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$1,000,000
R44 · FY2021 · CA · contact PI
Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations$398,768
R43 · FY2021 · CA · contact PI
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$1,000,000
R44 · FY2020 · CA · contact PI
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,333
R44 · FY2019 · CA · contact PI
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$224,831
R43 · FY2018 · CA · contact PI
A repurposed molecule as an oral therapeutic to improve vascular flow in sickle cell disease$224,553
R43 · FY2018 · HL · contact PI
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$1
R44 · FY2018 · CA · contact PI
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,914
R44 · FY2017 · CA · contact PI
The Translational Development of a Therapeutic For Triple Negative Breast Cancer$749,960
R44 · FY2016 · CA · contact PI
A targeted drug for the treatment of inflammation in cystic fibrosis lung disease$224,958
R43 · FY2016 · HL · contact PI
Schiff base forming sunscreen filters for long-wear UV protection$750,000
R44 · FY2015 · CA · contact PI
The Translational Development of a Therapeutic For Triple Negative Breast Cancer$749,959
R44 · FY2015 · CA · contact PI
A targeted immunomodulator for the treatment of acute sickle crisis$224,901
R43 · FY2015 · TR · contact PI
Organocatalysis for the treatment of sickle cell disease$1,228,297
R44 · FY2014 · HL · contact PI
Schiff base forming sunscreen filters for long-wear UV protection$749,999
R44 · FY2014 · CA · contact PI
Orally available transition state inhibitors for triple negative breast cancer$225,000
R41 · FY2014 · CA · contact PI
Organocatalysis for the treatment of sickle cell disease$1,367,340
R44 · FY2013 · HL · contact PI
Schiff base forming sunscreen filters for long-wear UV protection$250,540
R43 · FY2012 · CA · contact PI
Organocatalysis for the Treatment of Sickle Cell Disease.$243,469
R43 · FY2011 · HL · contact PI